HRP20050277A2 - Medicament containing disorazoles and derivativesthereof for the treatment of benign and malignanttumoral diseases - Google Patents
Medicament containing disorazoles and derivativesthereof for the treatment of benign and malignanttumoral diseases Download PDFInfo
- Publication number
- HRP20050277A2 HRP20050277A2 HR20050277A HRP20050277A HRP20050277A2 HR P20050277 A2 HRP20050277 A2 HR P20050277A2 HR 20050277 A HR20050277 A HR 20050277A HR P20050277 A HRP20050277 A HR P20050277A HR P20050277 A2 HRP20050277 A2 HR P20050277A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- disorazole
- treatment
- general formula
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40559402P | 2002-08-24 | 2002-08-24 | |
| PCT/EP2003/009329 WO2004024149A1 (de) | 2002-08-24 | 2003-08-22 | Arzneimittel enthaltend disorale und ihre derivate und deren anwendung zur behandlung gutartiger und bosärtiger tumorerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050277A2 true HRP20050277A2 (en) | 2005-04-30 |
Family
ID=31993935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050277A HRP20050277A2 (en) | 2002-08-24 | 2003-08-22 | Medicament containing disorazoles and derivativesthereof for the treatment of benign and malignanttumoral diseases |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040106662A1 (enExample) |
| EP (1) | EP1536789A1 (enExample) |
| JP (1) | JP2006500398A (enExample) |
| KR (1) | KR20050038632A (enExample) |
| CN (1) | CN1678310A (enExample) |
| AR (1) | AR042617A1 (enExample) |
| AU (1) | AU2003296872B2 (enExample) |
| BR (1) | BR0313789A (enExample) |
| CA (1) | CA2438001A1 (enExample) |
| HR (1) | HRP20050277A2 (enExample) |
| IL (1) | IL166588A0 (enExample) |
| MX (1) | MXPA05002157A (enExample) |
| NO (1) | NO20051444L (enExample) |
| NZ (1) | NZ538926A (enExample) |
| PL (1) | PL376407A1 (enExample) |
| RU (1) | RU2322236C2 (enExample) |
| TW (1) | TW200404537A (enExample) |
| UA (1) | UA79480C2 (enExample) |
| WO (1) | WO2004024149A1 (enExample) |
| ZA (1) | ZA200501196B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20160631T1 (hr) * | 2006-09-06 | 2016-07-15 | Æterna Zentaris Gmbh | Konjugati disorazola i njihovi derivati sa staničnovezajućim molekulama, novi derivati disorazola, postupci njihove pripreme i njihove uporabe |
| BRPI0716190A2 (pt) * | 2006-09-06 | 2013-11-12 | Aeterna Zentaris Gmbh | Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos |
| EP1900742A1 (en) | 2006-09-07 | 2008-03-19 | AEterna Zentaris GmbH | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| WO2018237178A1 (en) * | 2017-06-22 | 2018-12-27 | William Marsh Rice University | Synthesis of disorazoles and analogs thereof as potent anticancer agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19605024A1 (de) * | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| EA007205B1 (ru) * | 2001-07-31 | 2006-08-25 | Вейне Стейт Юниверсити | Производные хинолина и их использование в качестве противоопухолевых средств |
| UA79293C2 (en) * | 2002-07-03 | 2007-06-11 | Univ Wayne State | 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents |
| WO2004053065A2 (en) * | 2002-12-06 | 2004-06-24 | Kosan Biosciences, Inc. | Disorazole polyketide synthase encoding polynucleotides |
-
2003
- 2003-08-22 CN CNA038200937A patent/CN1678310A/zh active Pending
- 2003-08-22 WO PCT/EP2003/009329 patent/WO2004024149A1/de not_active Ceased
- 2003-08-22 KR KR1020057003109A patent/KR20050038632A/ko not_active Ceased
- 2003-08-22 BR BR0313789-9A patent/BR0313789A/pt not_active IP Right Cessation
- 2003-08-22 AU AU2003296872A patent/AU2003296872B2/en not_active Ceased
- 2003-08-22 NZ NZ538926A patent/NZ538926A/xx unknown
- 2003-08-22 UA UAA200501355A patent/UA79480C2/uk unknown
- 2003-08-22 HR HR20050277A patent/HRP20050277A2/hr not_active Application Discontinuation
- 2003-08-22 TW TW092123217A patent/TW200404537A/zh unknown
- 2003-08-22 AR ARP030103050A patent/AR042617A1/es unknown
- 2003-08-22 MX MXPA05002157A patent/MXPA05002157A/es active IP Right Grant
- 2003-08-22 EP EP03794920A patent/EP1536789A1/de not_active Withdrawn
- 2003-08-22 RU RU2005108570/15A patent/RU2322236C2/ru not_active IP Right Cessation
- 2003-08-22 JP JP2004535140A patent/JP2006500398A/ja not_active Withdrawn
- 2003-08-22 US US10/646,904 patent/US20040106662A1/en not_active Abandoned
- 2003-08-22 PL PL03376407A patent/PL376407A1/xx not_active Application Discontinuation
- 2003-08-22 CA CA002438001A patent/CA2438001A1/en not_active Abandoned
-
2005
- 2005-01-31 IL IL16658805A patent/IL166588A0/xx unknown
- 2005-02-10 ZA ZA2005/01196A patent/ZA200501196B/en unknown
- 2005-03-18 NO NO20051444A patent/NO20051444L/no not_active Application Discontinuation
-
2009
- 2009-04-07 US US12/263,981 patent/US20090311264A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0313789A (pt) | 2005-07-05 |
| TW200404537A (en) | 2004-04-01 |
| JP2006500398A (ja) | 2006-01-05 |
| IL166588A0 (en) | 2006-01-15 |
| RU2005108570A (ru) | 2005-08-27 |
| RU2322236C2 (ru) | 2008-04-20 |
| NO20051444L (no) | 2005-05-19 |
| CA2438001A1 (en) | 2004-02-24 |
| NZ538926A (en) | 2006-03-31 |
| KR20050038632A (ko) | 2005-04-27 |
| US20090311264A1 (en) | 2009-12-17 |
| AU2003296872A1 (en) | 2004-04-30 |
| ZA200501196B (en) | 2005-10-26 |
| CN1678310A (zh) | 2005-10-05 |
| WO2004024149A1 (de) | 2004-03-25 |
| AR042617A1 (es) | 2005-06-29 |
| UA79480C2 (en) | 2007-06-25 |
| EP1536789A1 (de) | 2005-06-08 |
| PL376407A1 (en) | 2005-12-27 |
| MXPA05002157A (es) | 2005-05-23 |
| US20040106662A1 (en) | 2004-06-03 |
| AU2003296872B2 (en) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11542262B2 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| EP2947086B1 (en) | Novel fused pyrimidine compound or salt thereof | |
| JP2022531609A (ja) | 新規メチルキナゾリノン誘導体 | |
| US12233128B2 (en) | Degraders that target ALK and therapeutic uses thereof | |
| CN117642408A (zh) | 含硒杂环类化合物及其药用组合物和应用 | |
| WO2017086830A1 (ru) | Замещенные n-{3-[4-(1-метил-1н-индол-3-ил) пиримидин-2-иламино]-4-метокси-фенил}-амиды в качестве модуляторов egfr, предназначенные для лечения рака | |
| EP3823957A1 (en) | Inhibitors of hepatitis b virus | |
| CN109153672A (zh) | Trpv4拮抗剂 | |
| US20090311264A1 (en) | Use of Disorazoles and Their Derivatives for the Treatment of Benign and Malignant Oncoses | |
| JP2023554391A (ja) | キナーゼ阻害剤およびそれらの使用 | |
| KR102668390B1 (ko) | 신규한 pan-RAF 키나아제 저해제 및 이의 용도 | |
| CN121240859A (zh) | 用于治疗健康状况的组合物和制备和使用小分子的方法 | |
| WO2010038428A1 (ja) | タキサン系抗がん剤の置き換え薬 | |
| CN108864101B (zh) | 氘代sgx523 及其用途 | |
| HK1081458A (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
| CN105801563B (zh) | 吡唑类衍生物及其用途 | |
| HK40076424A (en) | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine | |
| EP3825318A1 (en) | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | |
| HK40060172B (en) | Phosphatidylinositol 3-kinase inhibitors | |
| HK40060172A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| AU2020286962A1 (en) | Heterocyclic immunomodulators as PDL1 checkpoint inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: ZENTARIS GMBH, DE |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090820 Year of fee payment: 7 |
|
| OBST | Application withdrawn |